Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.

IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.

In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).

According to our (Global Info Research) latest study, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size was valued at US$ 1594 million in 2023 and is forecast to a readjusted size of USD 3173 million by 2030 with a CAGR of 10.4% during review period.

North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.

This report is a detailed and comprehensive analysis for global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Sales Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size and forecasts, by Type and by Sales Channel, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is split by Type and by Sales Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Sales Channel in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
XIFAXAN
Viberzi
Lotronex
Other

Market segment by Sales Channel
Hospitals Pharmacy
Retail Pharmacy
Other

Major players covered
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with price, sales quantity, revenue, and global market share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs from 2019 to 2024.

Chapter 3, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Sales Channel, with sales market share and growth rate by Type, by Sales Channel, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market forecast, by regions, by Type, and by Sales Channel, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.

Chapter 14 and 15, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales channel, distributors, customers, research findings and conclusion.